Autolus Therapeutics (AUTL) Projected to Post Earnings on Thursday

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) is projected to issue its quarterly earnings data before the market opens on Thursday, March 20th. Analysts expect the company to announce earnings of ($0.21) per share and revenue of $2.98 million for the quarter. Parties that wish to register for the company's conference call can do so using this link.

Autolus Therapeutics Trading Down 2.9 %

Shares of NASDAQ:AUTL traded down $0.06 during trading on Friday, reaching $2.01. 443,981 shares of the company traded hands, compared to its average volume of 1,237,897. The firm has a market capitalization of $534.85 million, a price-to-earnings ratio of -1.66 and a beta of 2.07. Autolus Therapeutics has a 52-week low of $1.68 and a 52-week high of $6.63. The business's fifty day moving average is $2.14 and its 200-day moving average is $3.06.

Analysts Set New Price Targets

A number of brokerages recently commented on AUTL. The Goldman Sachs Group raised Autolus Therapeutics from a "neutral" rating to a "buy" rating and raised their price target for the stock from $7.00 to $7.60 in a research note on Monday, November 18th. Redburn Atlantic raised Autolus Therapeutics from a "neutral" rating to a "buy" rating and set a $13.00 price target for the company in a research note on Friday, November 15th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $10.00 price target on shares of Autolus Therapeutics in a research note on Monday, January 13th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $10.40.

Remove Ads

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.